The Medicines and Healthcare products Regulatory Agency (MHRA) has granted Myqorzo (aficamten) a marketing authorisation across the UK for the treatment of symptomatic (New York Heart Association, NYHA class II-III) obstructive hypertrophic cardiomyopathy (oHCM). At the same time, the National Institute for Health and Care Excellence (NICE) has issued guidance recommending aficamten for use in […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!